MedTrace Logo

Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies Beyond the Season

NCT04530786 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-10-23

No results posted yet for this study

Summary

This a sub-study of a 5-year study designed to investigate how antibody and T cell responses following influenza vaccine compare among lung transplant patients, patients waiting for lung transplantation, and healthy individuals.

This study is designed to investigate influenza vaccine-induced antibodies in lung transplant patients beyond the season of vaccination.

Conditions

Interventions

DRUG

Influenza vaccine

influenza vaccine 0.5 ml intramuscularly each season, antigens measured for 3 years following vaccination in: * 2004-2005: A/Wyoming H3N2; B/Shanghai * 2006-2007: A/New Caledonia H1N1 * 2007-2008: A/Solomon Islands; A/Wisconsin H3N2; B/Malaysia

Sponsors & Collaborators

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Mary S Hayney, PharmD · University of Wisconsin, Madison

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2009-07-31
Completion
2009-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04530786 on ClinicalTrials.gov